These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 11878450)

  • 1. The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis.
    Delmas PD; Calvo G; Boers M; Abadie E; Avouac B; Kahan A; Kaufman JM; Laslop A; Lekkerkerker JF; Nilsson P; Van Zwieten-Boot B; Kreutz G; Reginster JY;
    Osteoporos Int; 2002 Jan; 13(1):1-5. PubMed ID: 11878450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
    JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of nonrandomized trials with slow-release sodium fluoride with a randomized placebo-controlled trial in postmenopausal osteoporosis.
    Pak CY; Adams-Huet B; Sakhaee K; Bell NH; Licata A; Johnston C; Rubin B; Bonnick S; Piziak V; Graham H; Ballard J; Berger R; Fears W; Breslau N; Rubin C
    J Bone Miner Res; 1996 Feb; 11(2):160-8. PubMed ID: 8822339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint.
    Marcus R; Wong M; Heath H; Stock JL
    Endocr Rev; 2002 Feb; 23(1):16-37. PubMed ID: 11844743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data.
    Miller PD
    Curr Med Res Opin; 2008 Jan; 24(1):107-19. PubMed ID: 18031594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
    O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of herbal medicine BHH10 in postmenopausal women with osteoporosis: study protocol for a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial.
    Cho Y; Lee S; Kim J; Kang JW; Baek YH; Seo BK; Lee JD
    Trials; 2018 Sep; 19(1):482. PubMed ID: 30201024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
    Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
    Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men.
    Reginster JY; Abadie E; Delmas P; Rizzoli R; Dere W; der Auwera P; Avouac B; Brandi ML; Daifotis A; Diez-Perez A; Calvo G; Johnell O; Kaufman JM; Kreutz G; Laslop A; Lekkerkerker F; Mitlak B; Nilsson P; Orloff J; Smillie M; Taylor A; Tsouderos Y; Ethgen D; Flamion B
    Osteoporos Int; 2006 Jan; 17(1):1-7. PubMed ID: 16091835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide.
    Reginster JY; Hattersley G; Williams GC; Hu MY; Fitzpatrick LA; Lewiecki EM
    Calcif Tissue Int; 2018 Nov; 103(5):540-545. PubMed ID: 29951742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture.
    Palacios S; Silverman SL; de Villiers TJ; Levine AB; Goemaere S; Brown JP; De Cicco Nardone F; Williams R; Hines TL; Mirkin S; Chines AA;
    Menopause; 2015 Aug; 22(8):806-13. PubMed ID: 25668306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics.
    D'Agostino RB; Massaro JM; Sullivan LM
    Stat Med; 2003 Jan; 22(2):169-86. PubMed ID: 12520555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan.
    Ohta H; Solanki J
    Osteoporos Int; 2015 Mar; 26(3):849-63. PubMed ID: 25448837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
    Ettinger B; Black DM; Mitlak BH; Knickerbocker RK; Nickelsen T; Genant HK; Christiansen C; Delmas PD; Zanchetta JR; Stakkestad J; Glüer CC; Krueger K; Cohen FJ; Eckert S; Ensrud KE; Avioli LV; Lips P; Cummings SR
    JAMA; 1999 Aug; 282(7):637-45. PubMed ID: 10517716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etidronate and alendronate in the treatment of postmenopausal osteoporosis.
    Beauchesne MF; Miller PF
    Ann Pharmacother; 1999 May; 33(5):587-99. PubMed ID: 10369624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is it ethical to use placebos in osteoporosis trials?
    Ragi-Eis S; Zerbini CA; Provenza JR; Griz LH; de Gregório LH; Russo LA; Silva NA; Borges JL; de Souza AC; Castro ML; Lewiecki EM
    J Clin Densitom; 2006; 9(3):274-80. PubMed ID: 16931344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.